Silence Therapeutics And Quark Pharmaceuticals Expand Strategic Licensing Agreement.
03-Aug-2007 -
Silence Therapeutics plc and Quark Pharmaceuticals, Inc., announced an expansion of their current strategic technology licensing agreement.
In April 2005 the companies signed an Option and Licence Agreement, which provided Quark with access to Silence Therapeutics' novel proprietary siRNA ...
clinical trials
milestone payments
Pfizer